References
1.Baxter Healthcare Corporation. Reglan [Package Insert.] Deerfield, IL, Baxter Healthcare Corporation, 2003.
2.Sirota RA, Kimmel PL, Trichtinger MD, et al. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med 1986;146:2070–2071.
3.Indo T, Ando K. Metoclopramide-induced parkinsonism. Clinical characteristics of ten cases. Arch Neurol 1982;39:494–496.
4.Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J 1982;126:23–25.
5.Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486–2492.
6.Mazza A, Ruffatti S, Pessina AC, et al. Tetanus-like syndrome secondary to metoclopramide administration. Ann Ital Med Int 2000;15:301–302.
7.Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med 1992;1:271–278.
8.Dubow JS, Leikin J, Rezak M. Acute chorea associated with metoclopramide use. Am J Ther 2006;13:543–544.
9.Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull 2002;36:82–93.
10.Hyser CL, Drake ME Jr. Myoclonus induced by metoclopramide therapy. Arch Intern Med 1983;143:2201–2202.
11.Weddington WW Jr, Banner A. Organic affective syndrome associated with metoclopramide: case report. J Clin Psychiatry 1986;47:208–209.
12.Fishbain DA, Rogers A. Delirium secondary to metoclopramide hydrochloride. J Clin Psychopharmacol 1987;7:281–282.
13.Cunningham D, Dicato M, Verweij J, et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone, plus lorazepam. Ann Oncol 1996;7:277–282.
14.Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008;23:401–404.
15.Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med 1990;6:269–283.
16.Adams C. Metoclopramide and depression. Ann Intern Med 1985;103:960.
17.Friend K, Young R. Late-onset major depression with delusions after metoclopramide treatment. Am J Geriatr Psychiatry 1997;5:79–82.
18.Masters JC, O'Grady M. Adverse reactions to metoclopramide (reglan) presenting as depression in a bone marrow transplant patient. Medsurg Nurs 1995;4:481–485.
19.Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230–1234.
20.Tornetta FJ. Clinical studies with the new antiemetic, metoclopramide. Anesth Analg 1969;48:198–204.
21.Eggers C. [Non-delirious toxic psychoses in children.] Z Kinderheilkd 1975;119:71–86 [in German].
22.Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53–83.
23.Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000;16:365–379.
24.Mehta MA, Sahakian BJ, McKenna PJ, et al. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl) 1999;146:162–174.
25.Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain Behav 2006;5:311–328.